[Radical prostatectomy. A review of our series between 1997-2003]. / Prostatectomía radical. Revisión de nuestra serie en el periodo 1997-2003.

OBJECTIVE: To evaluate the complications and results of our series of 398 radical retropubic prostatectomies as an elective treatment for clinically localized prostate cancer. PATIENTS AND METHODS: Between January 1997 and June 2003, a total of 398 radical retropubic prostatectomies have been performed. Mean age was 63.8 years (45.8-78.2), mean PSA at diagnosis 9.32 ng/ml (0.9-129.7). Mean surgical time was 141.6 minutes (70-280), and mean hospitalization was 6.75 days (2-37). RESULTS: Mean follow-up was 65.18 months. We report as peroperatory complications: rectal injury 1.8%, lymphatic leakage 0.3%, urinary fistula 5%. As delay complications: uretrovesical junction stenosis 6%. We observed 49.1% of patients with positive surgical margins. We don't report any peroperatory death. The overall survival rate is 98.5%, the cancer specific survival rate is 99.75%, and the recurrence-free survival rate is 84.97%. CONCLUSIONS: Radical retropubic prostatectomy is an excellent treatment form for patients with clinically localized prostate cancer. A strict selection of patients candidates is important to obtain good results.

Prostatectomía radical. Revisión de nuestra serie en el periodo 1997-2003 / Radical prostactectomy. A review of our serie between 1997-2003

Objetivos: Analizar los resultados y complicaciones de nuestra serie de 398 casos de prostatectomía radical retropúbica como tratamiento electivo del cáncer de próstata órgano confinado. Material y metodos: Entre enero de 1997 y junio de 2003 hemos realizado un total de 398 prostatectomías radicales. La edad media fue de 63,8 años (45,8-78,2), con una media de PSA al diagnóstico de 9,32 ng/ml (0,9-129,7). La media del tiempo quirúrgico es de 141,6 minutos (70-280), y la media de días de ingreso hospitalario de 6,75 días (2-37).Resultados: El seguimiento medio de nuestra serie ha sido de 65,18 meses. Como complicaciones peroperatorias destacamos: lesión rectal 1,8%, linforrea 0,3%, fístula urinaria 5%. Como complicaciones tardías: estenosis anastomosis uretrovesical 6%.Hemos objetivado un porcentaje de márgenes positivos del 49,1%. No hemos tenido ningún exitusperoperatorio. La supervivencia global de la serie es del 98,5%, la supervivencia cáncer específica del 99,75%, y la supervivencia libre de enfermedad del 84,97%.Conclusiones: La prostatectomía radical es una excelente opción de tratamiento en pacientes con cáncer de próstata órgano confinado. Es indispensable para obtener buenos resultados una correcta selección de los pacientes candidatos a tratamiento quirúrgico (AU)

Objetive: To evaluate the complications and results of our series of 398 radical retropubic prostatectomies as an elective treatment for clinically localized prostate cancer. Patients and methods: Between january 1997 and june 2003, a total of 398 radical retropubic prostatectomies have been performed. Mean age was 63.8 years (45.8-78.2), mean PSA at diagnosis 9.32 ng/ml (0.9-129.7). Mean surgical time was 141.6 minutes (70-280), and mean hospitalization was 6.75 days (2-37). Results: Mean follow-up was 65.18 months. We report as peroperatory complications: rectal injury 1.8%, lymphatic leakage 0.3%, urinary fistula 5%. As delay complications: uretrovesical junction stenosis 6%. We observed 49.1% of patients with positive surgical margins. We don´t report any peroperatory death. The overall survival rate is 98.5%, the cancer specific survival rate is 99.75%, and the recurrence-free survival rate is 84.97%. Conclusions: Radical retropubic prostatectomy is an excellent treatment form for patients with clinically localized prostate cancer. A strict selection of patients candidates is important to obtain good results (AU)

[Retrospective study of 130 patients with organconfined prostate cancer treated with brachytherapy]. / Estudio retrospectivo de 130 pacientes con cáncer prostático organoconfinado tratados con braquiterapia prostática.

INTRODUCTION: The prostate brachytherapy with I 125 seeds has an indication in patients with organconfined prostate cancer. Our objective is to describe the population treated in our institution with permanent I125 seeds implants, the dosimetric characteristics of the technique and the preliminary results of our group-study in terms of evolution and toxicity. MATERIAL AND METHODS: Between May 2000 and March 2003, 130 patients with permanent implants of I125 seeds were treated. Beforehand we did prostate volumetric with transrectum prostate echography in order to assess the configuration of the implant, number of seeds and their place in the prostate with the objective to get a fine coverage of PTV (planet target volume). Stage distribution: 75.72% T1c; 24.28% T2a; Gleason<6, 94%. The PSA pretreatment average was 6.38 ng/ml. The average prostate volume was 30 cc. The 16.67% of the patients included had hormonal treatment previously to get the implants. The average age was 64 years. The characteristic techniques of the implants were: the average width of the needle as 24 (14-35) and the average of the seeds 76 (46-111). Finally the average activity was 0.39 mCi/seed, which means average total implant activity of 80 mCi. RESULTS: We analyzed 130 patients with average follow up 6 months. A 1 to 2 year surveillance was carried out on 98.9% and the global free disease surveillance (biochemic relapse) of 98.9% at the year and of the 87.8% at the end of the 2 years. The relapse in the low risk patients was 98.8% after the first year and 88.7% at the end of 2 year. On the contrary in the middle risk was of 100% and 83% respectively, although the amount of patients in significantly less. As a relevant acute secondary effects we found slight rectitys or GI (RTOG scale) in 1.4 and that needs synthomatic medication or GII (RTOG scale) in 0.8%. We found slide hematuria or GI (RTOG scale) in the 53% and other measures or GII (RTOG scale) in the 2.64% was needed. Finally we had to set a urinary prove for acute retention in 4.3%. CONCLUSION: The prostate brachyterapy is a complex procedure that needs a multidisciplinary team participation in order to be able to carry out. It avoids a long term hospitalization and allows for the patient to have daily activity within a short period of time. Despite the fact of the brief follow-up, the results over biochemical relapse and toxicity were similar to the ones in the literature. Tolerance to the implant was good. It would necessary a longer follow-up in order to be able to come to long term conclusions.

Estudio retrospectivo de 130 pacientes con cáncer prostático organoconfinado tratados con braquiterapia prostática / Retrospective study of 130 patients with organconfined prostate cancer trated with brachitherapy

Introducción: La braquiterapia prostática con semillas de I125 está indicada en pacientes con cáncer de próstata organoconfinado. Nuestro objetivo es describir la población tratada en nuestra institución mediante implante permanente con semillas de I125, las características dosimétricas de la técnica y los resultados preliminares de nuestra serie en cuanto a evolución y toxicidad. Material y métodos: Entre mayo 2000 y marzo de 2003 fueron tratados 130 pacientes con implante permanente transperineal de semillas de I125. Previamente a todos se les realizó volumetría mediante una ecografía prostática transrectal para determinar la configuración del implante, número de semillas y su localización en la próstata con el fin de obtener una adecuada cobertura del PTV (planed target volume o volumen planificado para tratar). Distribución por estadios: 75,72% T1c; 24,28% T2a. Gleason < 6, 94,24%. La mediana del PSA pretratamiento 6,38 ng/ml. El volumen prostático mediano fue de 30 cc. El 16,67% de los pacientes cuando los recibimos llevaban tratamiento hormonal previo al implante. La edad mediana fue de 64 años. En cuanto a las características técnicas de los implantes: la mediana de agujas utilizadas fue de 24 (14-35), y la mediana de semillas: 76 (46-111). Finalmente la mediana de la actividad fue de 0,39mCi/semilla, lo que supuso una actividad total implantada media de 80 mCi. Resultados: Analizamos los 130 pacientes con un seguimiento mínimo de 6 meses. La supervivencia a 1 y 2 años fue del 99,1% y la supervivencia libre de enfermedad global del 98,9% al año y del 87,8% a los dos años La supervivencia libre de enfermedad bioquímica en los pacientes de bajo riesgo eran, al año de 98,8% y a los dos años del 88,7%. Por el contrario en los de riesgo intermedio eran del 100% y del 83,3% respectivamente, aunque el número de pacientes es significativamente menor. Como efectos secundarios agudos relevantes encontramos rectitis leve o GI (escala de la RTOG) en 1,4% y que necesitó medicación sintomática o GII (escala de la RTOG) en 0,8%. Se presentó hematuria leve o GI (escala de la RTOG) el 53%, y que precisaran otras medidas o GII (escala de la RTOG) en el 2,64%. Finalmente hubo que colocar sonda urinaria por retención aguda el 4,3%. Conclusión: La braquiterapia prostática es un procedimiento complejo que exige la participación de un equipo multidisciplinar en su realización. Evita una hospitalización prolongada y permite al paciente recuperar sus actividades cotidianas en un periodo corto de tiempo. Aunque la media de seguimiento es corta, los resultados en cuanto a supervivencia libre de recidiva bioquímica y toxicidad son comparables a los descritos en la literatura. La tolerancia al implante ha sido buena. Es necesario un mayor seguimiento para poder establecer conclusiones a largo plazo

Introduction: The prostate brachitherapy with I 125 seeds has an indication in patients with organconfined prostate cancer. Our objective is to describe the population trated in our institution with permanent I125 seeds implants, the dosimetric characteristics of the technique and the preliminary results of our group-study in terms of evolution and toxicity. Material and methods: Between May 2000 and March 2003, a 130 patients with permanent implants of I125 seeds were trated. Beforehand we did prostate volumetric with transrectum prostate ecography in order to asses the configuration of the implant, number of seeds and their place in the prostate with the objective to get a fine coverage of PTV (planet target volume). Stage distribution: 75.72% T1c; 24.28% T2a. Gleason<6, 94%. The PSA pretreatment average was 6.38 ng/ml. The average prostate volume was 30 cc. The 16.67% of the patients included had hormonal treatment previously to get the implants. The average age was 64 years. The characteristic techniques of the implants were: the average width of the needle as 24 (14-35) and the average of the seeds 76 (46-111). Finally the average activity was 0.39 mCi/seed, wic means average total implant activity of 80 mCi. Results: We analized 130 patients with average follow up 6 months. A 1 to 2 year surveillance was carried out on 98.9% and the global free disease surveillance (biochemic relapse) of 98.9% at the year and of the 87.8% at the end of the 2 years. The relapse in the low risk patients was, 98.8% after the first year and 88.7% at the end of 2 year. On the contrary in the middle risk was of 100% and 83% respectively, although the amount of patients in significantly less. As a relevant acute secondary effects we found slight rectitys or GI (RTOG scale) in 1.4 and that needs synthomatic medication or GII (RTOG scale) in 0.8%. We found slide hematuria or GI (RTOG scale) in the 53% and other measures or GII (RTOG scale) in the 2.64% was needed. Finally we had to set a urinary prove for acute retention in 4.3%. Conclusion: The prostate brachiterapy is a complex procedure that needs a multidisciplinary team participation in order to be able to carry out. It aboids a long term hospitalitzation and allows for the patient to have daily activity within a short period of time. Despite the fact of the brief follow-up, the results over biochemical relaps and toxicity were similars to the ones in the literature. Tolerance to the implant was good. It would necessary a longer follow-up in order to be able to come to long term conclusions

[Primary bladder actinomycosis]. / Actinomycosis vesical primaria.

Primary actinomycosis of the bladder is an infrequent presentation of this condition. The main concern is obtaining a differential diagnosis from tumours of the bladder and the subsequent impact this has on the therapeutic choices. Contribution of one case report of a male patient with actinomycosis of the bladder, with remarks on relevant diagnostic (including differential diagnosis) and therapeutic data.

Actinomycosis vesical primaria / Actinomycosis vesical primaria

La actinomicosis vesical primaria constituye una rara forma de presentación de esta enfermedad. Su principal problema radica en la realización del diagnóstico diferencial con procesos tumorales vesicales, con la consiguiente repercusión terapéutica. Presentamos el caso clínico de un paciente afecto de actinomicosis vesical, comentando los datos más relevantes en su diagnóstico (incluyendo el mencionado diagnóstico diferencial) y tratamiento (AU)

Ovarian tumors of low malignant potential (borderline). A retrospective study of 31 cases.

Thirty-one patients with ovarian tumors of low malignant potential (borderline) treated between 1982 and 1992 have been reviewed. The mean age was 46.3 years (range: 20-77). Postsurgical stage (FIGO) obtained was: I 24 (77.4%), II 2 (6.5%) and III 4 (12.9%). Histologic subtypes were mucinous 16 (48.3%), serous 12 (38.7%), endometrioid 1 (3.2%) and mixed type 2 (6.5%). All patients underwent primary surgical treatment and conservative surgery (unilateral oophorectomy) was performed in 8 (25.8%) young patients at early-stage. Ovarian tumors were bilateral in 3 (9.7%) of cases; peritoneal implants were found in 4 (14.3%) cases; and retroperitoneal nodal involvement was confirmed in 1 (3.2%) case. Only patients at advanced-stage received adjuvant chemotherapy (cisplatin-based). The survival rate obtained at 5 years was 100% for Stage IA, 96% for early-stage (I/II), and 75% for advanced-stage (III). Results were evaluated in order to assess clinicopathologic features, surgical approach, and outcome of borderline ovarian tumors.